Semaglutides—weight loss and diabetes injectables like Wegovy, Ozempic, and Rybelsus—significantly improved blood sugar control and weight in adults with type 2 diabetes over a three-year period, according to new data released Monday at a major endocrine conference.
Results of the study—funded by Ozempic manufacturer Novo Nordisk—were presented by the Israeli researchers at the annual meeting of the European Association for the Study of Diabetes in Hamburg, Germany.
